Ben Nassau
I’m joined by Gilad, the CFO of Protalix BioTherapeutics. And so, Gilad, maybe just to get started, for people in the audience who may be less familiar with Protalix, can you start by giving us the, let’s call it 30,000-foot view of the company, where it came from, what makes the technology distinctive, and where you see the company today?
Gilad Mamlok
Senior VP, CFO Treasurer & Secretary
Sure. Good afternoon everyone and thank you Ben and the Morgan Stanley team for inviting me. We are a pharmaceutical company focusing on rare disease assets in significant areas of unmet need. We built a profitable commercial company based on two products, Elelyso for Gaucher disease and Elfabrio for Fabry. Both are partnered with global commercial players. Elelyso is licensed to Pfizer worldwide, except for Brazil, where it’s licensed to Fiocruz, an arm of the Ministry of Health in Brazil, which is actually doing a very good job.
We have 27% share in Brazil, mainly attributable to the very good service and quality of service that they provide to patients, to the community, to the physicians, and that was $11 million of our revenues in 2025.
Elfabrio is licensed to Chiesi globally. Chiesi, for those who don’t know, is a privately owned company
Credit: Source link
